Pharmaron, Celgene, Amgen and Merck & Co-backed Imago BioSciences floated in an IPO today, alongside a private placement transaction featuring Pfizer.

Alexandria Venture Investments was among the participants in a series B round for Wugen, which is developing cellular therapeutics for cancer.

Patient Square Capital led a series B round for the gene therapy developer that included existing corporate investor Dexcel Pharma.

Takeda Ventures has brought on Mann as a senior partner who draws on extensive life sciences-focused venture capital experience.

Patient Square Capital has led a series B round for the Stanford-linked gene therapy developer, which previously collected $80.5m in May last year.

Clean medicine developer Genexa roped in Unilever for its $60m series A round while Krafton led storytelling platform developer Pratilipi's $48m series D.

The IGBMC spinout was set up by Satt Conectus and is now seeking a listing in the US with a price range of $15 to $17.

The price Eli Lilly is paying for protein drug developer and portfolio company Protomer could potentially top $1bn dependent on milestone payments.

Ionis Pharmaceuticals' stake in the muscular disease treatment developer will be cut in an offering set to raise between $95m and $107m.

All 17 founding health systems have chipped into the health data platform developer’s series A round, which closed with contributions from three new members.